Atypical experience: A case series of pediatric aripiprazole exposures

被引:23
作者
Lofton, AL [1 ]
Klein-Schwartz, W [1 ]
机构
[1] Univ Maryland, Sch Pharm, Maryland Poison Ctr, Dept Pharm Practice & Sci, Baltimore, MD 21201 USA
关键词
aripiprazole; toxicity; overdose; pediatric;
D O I
10.1081/CLT-200053095
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Background: Aripiprazole is a new psychotropic agent that possesses a unique pharmacologic profile. The drug demonstrates mixed dopamine and serotonin agonist-antagonist activity and has been labeled a third-generation antipsychotic and dopamine-serotonin system stabilizer. Overdose experience is limited, especially in pediatrics. Case Series: Of five pediatric cases identified, toxicity was mainly evident in younger patients. A 2-year-old who ingested 40 mg experienced vomiting and significant lethargy lasting approximately 30 h. A 6-year-old who received two doses of aripiprazole therapeutically experienced lethargy, drooling, and flaccid facial muscles which improved with diphenhydramine. Two adolescents remained asymptomatic despite doses of 120 mg and 300 mg while a third adolescent with an unknown dose experienced transient lethargy. Conclusion: Aripiprazole is capable of producing marked lethargy and gastrointestinal upset in pediatric patients. Adolescents in this series experienced only minor, if any, clinical effects. Major clinical effects, i.e., seizures, dysrhythmias, were not reported in this series.
引用
收藏
页码:151 / 153
页数:3
相关论文
共 10 条
  • [1] Blumer JL, 2002, CLIN PHARMACOL THER, V71, pP5
  • [2] *BRIST MYERS SQUIB, 2003, AB AR
  • [3] Excessive somnolence from aripiprazole in a child
    Davenport, JD
    McCarthy, MW
    Buck, ML
    [J]. PHARMACOTHERAPY, 2004, 24 (04): : 522 - 525
  • [4] Schizophrenia
    Freedman, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (18) : 1738 - 1749
  • [5] Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
    Marder, SR
    McQuade, RD
    Stock, E
    Kaplita, S
    Marcus, R
    Safferman, AZ
    Saha, A
    Ali, M
    Iwamoto, T
    [J]. SCHIZOPHRENIA RESEARCH, 2003, 61 (2-3) : 123 - 136
  • [6] National trends in the use of psychotropic medications by children
    Olfson, M
    Marcus, SC
    Weissman, MM
    Jensen, PS
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2002, 41 (05) : 514 - 521
  • [7] Childhood-onset schizophrenia: Premorbid and prodromal diagnostic and treatment histories
    Schaeffer, JL
    Ross, RG
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2002, 41 (05) : 538 - 545
  • [8] Seifert S. A., 2003, Journal of Toxicology Clinical Toxicology, V41, P647
  • [9] Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, Part 2 - Illustrating their mechanism of action
    Stahl, SM
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (12) : 923 - 924
  • [10] Taylor DM, 2003, INT J CLIN PRACT, V57, P49